Table 1—

Lipid and lipoprotein abnormalities at fasting and postprandial states in human genetic CD36 deficiency

Group A
Group B
Case 1Case 2Control (n = 4)Case 3Case 4Case 5Case 6Case 7Control (n = 8)
Age (years)/sex (M/F)34/M32/M33 ± 2 (4M)58/M65/F54/F54/F54/M55 ± 10 (3M/5F)
BMI (kg/m2)22.932.022.4 ± 1.026.222.232.817.324.922.7 ± 2.3
WBGU (mg · kg−1 · min−1)*7.82.89.1 ± 0.52.677.095.494.855.298.6 ± 0.5
Fasting state
 Total cholesterol (mmol/l)4.205.014.78 ± 0.385.816.185.975.455.845.10 ± 0.69
 Triglyceride (mmol/l)0.781.231.00 ± 0.172.731.431.771.283.411.20 ± 0.38
 Midband in PAG disc  electrophoresis+++++
 IDL cholelsterol (mmol/l)§NDND0.480.380.290.340.220.11 ± 0.03
Postprandial state
 AUC-TG (mmol/l 6 h)5.38.88.8 ± 0.720.613.414.014.026.810.0 ± 2.9
 AUC-Apo B48 (AU/ml 6 h)**223268329 ± 107866671941551541360 ± 120
  • Data are means ± SD unless otherwise indicated. apo, apolipoprotein; AUC, area under the curve; PAG, polyacrylamide gel; WBGU, mean whole-body glucose uptake.

  • *

    * Insulin resistance was determined by euglycemic clamp technique (ref. 3);

  • part of data from cases 3–7 were described previously (Ref. 3);

  • lipoproteins were analyzed by PAG electrophotesis.

  • §

    § IDL was separated by preparative ultracentrifugation (1.019 < d < 1.063 g/ml);

  • postprandial hyperlipidemia was analyzed by the oral fat loading test with fat cream containing 30 g fat/m2 body surface area; TG and apo B48 levels were measured at 0, 2, 4, and 6 h after loading, and AUCs were calculated;

  • **

    ** serum apo B48 levels were measured by the enzyme-linked immunosorbent assay we have developed.